VH032 is primarily utilized in the field of biochemical research and drug discovery, particularly in the study of protein-protein interactions. It is known for its role as a potent and selective inhibitor of the von Hippel-Lindau (VHL) E3 ubiquitin ligase, which plays a critical role in the regulation of hypoxia-inducible factors (HIFs). By inhibiting VHL, VH032 is used to stabilize HIFs, allowing researchers to investigate cellular responses to hypoxia and explore potential therapeutic targets for conditions like cancer, where hypoxia and HIF signaling are often dysregulated. Additionally, VH032 is employed in the development of proteolysis-targeting chimeras (PROTACs), a novel drug modality that leverages the ubiquitin-proteasome system to degrade specific proteins of interest, offering a promising approach for targeted protein degradation in disease treatment.